Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Work In Process (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Work In Process for 2 consecutive years, with $4.3 million as the latest value for Q4 2025.

  • Quarterly Work In Process rose 77.0% to $4.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Dec 2025, up 77.0% year-over-year, with the annual reading at $4.3 million for FY2025, 77.0% up from the prior year.
  • Work In Process for Q4 2025 was $4.3 million at Day One Biopharmaceuticals, down from $6.0 million in the prior quarter.
  • The five-year high for Work In Process was $6.0 million in Q3 2025, with the low at $2.4 million in Q4 2024.